Jarden says a range of outcomes possible for Pacific Edge

Jarden says a range of outcomes possible for Pacific Edge
(Image: Pacific Edge)
Staff reporters
Pacific Edge has bought time to overturn a decision that would have seen Medicare coverage of Cxbladder cease in the US on July 17, but a range of outcomes are still possible, said Jarden.The investment house rates the stock at neutral with a 12-month target price of 16 cents. That view is based on “an equal weighting of Pacific Edge executing a survival workstream that requires investment in further evidence and with further equity support required and the other where this proves too difficult and Pacific Edge elects to wind down&rd...